Clinical Trial Update: Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of Bupropion hydrochloride extended-release 300 mg under fasting conditions sponsored by Teva has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Bupropion hydrochloride ER 300 mg tablet (bupropion hydrochloride)

Snippet

Sponsor: Teva Pharmaceuticals USA | Conditions: Depressive Disorder | Phase 1 | Status: TERMINATED